Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Bishop, Michael R., Maziarz, Richard T., Waller, Edmund K., Jäger, Ulrich, Westin, Jason R., McGuirk, Joseph P., Fleury, Isabelle, Holte, Harald, Borchmann, Peter, del Corral, Christopher, Tiwari, Ranjan, Anak, Özlem, Awasthi, Rakesh, Pacaud, Lida, Romanov, Vadim V., Schuster, Stephen J.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650727/
https://ncbi.nlm.nih.gov/pubmed/31332046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000151
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker